Table 11.6d

Immunosuppression Use: Antirejection Treatment from Transplant

to One Year Posttransplant, 1992 to 2001

Recipients with Heart Transplants

		Year of Transplant
		1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
Transplants		2,171	2,298	2,340	2,362	2,343	2,294	2,348	2,188	2,197	2,202
Tx with Antirejection Treatments		850	949	935	953	854	872	978	913	896	842
Antibodies	Category Usage	23.1%	26.6%	22.7%	20.8%	18.1%	19.3%	21.3%	17.7%	16.2%	15.7%
	ALG	0.0%	0.4%	1.8%	0.4%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	ATG	0.9%	3.6%	7.3%	7.2%	4.2%	6.0%	6.4%	6.1%	4.4%	3.8%
	NRATG/NRATS	0.0%	0.0%	0.4%	0.7%	1.2%	1.9%	0.8%	0.2%	0.0%	0.0%
	OKT3	22.4%	24.0%	16.7%	14.5%	13.9%	13.1%	14.9%	7.4%	5.1%	5.7%
	Thymoglobulin	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.2%	2.0%	3.8%	5.1%
	Zenapax	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.8%	2.5%	3.0%	2.5%
	Simulect	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.9%	2.0%	0.4%
Corticosteroids	Category Usage	91.4%	88.1%	89.4%	92.5%	88.3%	88.6%	87.9%	91.2%	92.2%	92.4%
	Steroids	91.4%	88.1%	89.4%	92.5%	88.3%	88.6%	87.9%	91.2%	92.2%	92.4%

Source: OPTN/SRTR Data as of August 1, 2003.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.